Medicaid Drug Rebates Offset Price Increases For Brands During 2005-2009, OIG Concludes
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite substantial price inflation, rebate-adjusted Medicaid payments for all branded drugs increased by only 2% over the four years in the study.
You may also be interested in...
Medicaid Gets Higher Rebates For Brand Drugs Compared To Medicare Part D, OIG Says
Findings could carry extra significance as congressional "super committee" looks for ways to cut at least $1.2 trillion in federal spending.
Rx Price Hikes In Advance Of Health Bill Will Get OIG Probe
Sen. Bill Nelson continues campaign to extract more concessions from pharmaceutical industry as part of health care reform legislation.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.